FDA sends warning letters to 30 telehealth firms over compounded GLP-1 claims
The agency says some marketed compounded semaglutide and tirzepatide as equal to approved drugs. Hims shares slipped, and firms have 15 working days to respond.
Recap by typeshit. Full story at Stocktwits.